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Diabetic ketoacidosis (DKA) is a serious manifestation of un ­
controlled blood sugar that can occur in patients with type 1 or 
type 2 diabetes mellitus (DM). There are three cornerstones of 
therapy: intravenous (IV) fluids, insulin therapy and management 
of electrolytes. Treatment of DKA has shown many advances over 
the years. It is now clear that low­dose insulin is as effective as high­
dose insulin in treating DKA, with a reduced rate of hypoglycaemia 
and hypokalaemia.[1] It is also known that an initial IV insulin bolus 
may not be needed in the management of DKA if insulin therapy is 
started promptly at a dose of 0.14 IU/kg/h.[2,3] There are several ways 
to administer insulin therapy, which have been evaluated: continuous 
IV infusion (CII) or bolus IV, subcutaneous (SC) or intramuscular 
(IM) insulin therapy. It is generally accepted that CII of insulin is 
the preferred method of treating DKA; this has been incorporated 
into treatment protocols worldwide.[4] Evidence evaluating different 
routes of insulin administration is weak or of low quality, and 
generally comprises consensus opinion.[5] High­quality randomised 
controlled trials (RCTs) are lacking and needed in this regard.[6] There 
have been only 5 RCTs evaluating SC bolus management of DKA 
compared with CII, which have found the latter to be an acceptable 
alternative in patients with mild to moderate DKA.[7] Specifically, 
there is a paucity of evidence supporting the bolus IV insulin route. 
The rationale behind evaluating the bolus insulin management 
of DKA stems from an anticipated cost and resource benefit in 
managing patients out of intensive care units (ICUs). CIIs require 
flow regulators and constant monitoring of the infusion – both are 
expensive and require a low nurse­to­patient ratio. Bolus insulin 
administration offers the benefit of not requiring flow regulators, 
which can save costs, and limits constant monitoring of the infusion, 
which would be required in an ICU setting. Blood glucose could be 
checked hourly when insulin boluses are administered and decreases 
work load for nursing staff. Despite assumptions that bolus insulin 
would result in a rapid peak and effect and subsequent absence of 
insulin during the remainder of the hour, clinically this does not seem 
to be the case.[8]
The Society for Endocrinology, Metabolism and Diabetes of 
South Africa (SEMDSA) guidelines, 2017, for the management of 
DKA, state that insulin therapy should ideally be provided as a CII 
in an ICU setting. Where an ICU is not available or there is delayed 
admission, insulin should be administered by hourly IV or IM 
boluses to decrease the incidence of hypoglycaemia.[9] The literature 
to support bolus IV administration of insulin includes small trials 
done >40 years ago, as well as studies done on the pharmacokinetic 
properties of insulin administered by different routes.[8,10­13] The 
results of these studies are difficult to apply in our current setting, as 
in some much higher doses of insulin were administered hourly and 
all contained very small sample sizes. This audit aims to fill a gap in 
the literature, especially in the SA setting, where bolus low­dose IV 
insulin can be used to safely treat patients with mild, moderate and 
severe DKA in a setting outside of the ICU.
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Background. Continuous intravenous infusion (CII) of insulin is the preferred method of treating diabetic ketoacidosis (DKA) worldwide, 
especially in patients with severe DKA. There is limited evidence evaluating low­dose bolus intravenous (IV) insulin management of DKA 
out of the intensive care unit (ICU).
Objectives. To conduct an audit of patients admitted with DKA, who were managed with bolus IV insulin at the medical acute­care unit 
(MACU), Chris Hani Baragwanath Academic Hospital (CHBAH), Johannesburg, South Africa, over a 4­month period to evaluate whether 
this is an effective treatment modality, as well as assess patient, disease and management characteristics related to the admissions.
Methods. A prospective cross­sectional cohort study was done, interviewing 69 DKA patients from 1 September to 31 December 2017, and 
collecting relevant biochemical results from their hospital records. The current management protocol at CHBAH was observed, i.e. insulin 
therapy administered hourly as 10 IU IV insulin. The time to resolution of DKA, complications and deaths were recorded. 
Results. Our cohort was predominantly male (60.56%), with an average age of 36 years. All patients were successfully treated with bolus IV 
insulin, with an average time to resolution of 21 hours. DKA was categorised as mild (19.72%), moderate (50.7%) and severe (29.58). Most 
patients presented with raised inflammatory markers (64.79%) and some degree of renal impairment (>60%). Complications occurred in 
9 patients (12.68%); 7 of these were related to factors precipitating the DKA admission. No deaths occurred. The only factor predicting a 
longer time to resolution was severity, with an odds ratio of 4.89 (confidence interval 1.04 ­ 22.84; p=0.044).
Conclusions. Outcomes are favourable, with bolus IV insulin being used as the treatment modality in patients with mild, moderate and 
severe DKA at CHBAH. Further studies are needed to corroborate these results in other centres.
S Afr Med J 2019;109(6):407­411. DOI:10.7196/SAMJ.2019.v109i6.13700
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Methods
Definitions
DKA is diagnosed according to the American Diabetes Association 
and SEMDSA guidelines:[9] pH <7.3 or bicarbonate <18 mmol/L and 
presence of ketonaemia. As serum ketones are not readily available, 
the presence of urine ketones are used as a surrogate marker. 
Severity is classified by pH: mild (7.25 ­ 7.3), moderate (7.0 ­ 7.24), 
severe (<7.0).
Resolution of DKA is classified as resolution of acidosis (pH >7.3, 
bicarbonate >18 mmol/L) and ketonaemia (<1 mmol/L). Similarly, 
urine ketones (1+ or 0) are used owing to resource constraints.
Objectives
The primary objective of this study was to determine if the bolus IV 
insulin method was effective in treating DKA. Secondly, we evaluated 
patient, disease and management characteristics in our cohort. 
Setting
This audit was done at Chris Hani Baragwanath Academic Hospital 
(CHBAH), a tertiary hospital in Soweto, Johannesburg, South 
Africa (SA), serving a wide catchment area (urban, semi­rural 
and rural). Patients with DKA are initially seen in the emergency 
department, where emergency measures are implemented when 
DKA is diagnosed (fluid bolus, insulin therapy and correction of 
electrolyte disturbances). The internal medicine department is then 
consulted and patients are transferred to either the medical acute­
care unit (MACU) or ICU, as deemed appropriate by the admitting 
registrar. The MACU was established in 2011 as a higher­care unit 
with a nurse­patient ratio of 1:2 ­ 1:3, where acutely ill, non­ventilated 
patients can be managed until stable for transfer to a general medical 
ward. It is a 12­bed unit with 4 ­ 5 nurses and covered by 1 medical 
registrar, who is supported by his/her medical intern. Patients with 
DKA are a large portion of those admitted to the MACU, with an 
average of 26.67 per month (Table 1). 
DKA is managed by 10 IU bolus IV insulin hourly, with blood 
gases checked every 2 ­ 4 hours until resolution is achieved. Insulin is 
not administered if hypoglycaemia is present. IV fluids (crystalloids) 
are administered and adjusted according to hourly finger­prick 
glucose readings and electrolytes, as monitored on serial blood gases. 
All patients aged >14 years admitted to CHBAH’s internal medicine 
department with a diagnosis of DKA during September ­ December 
2017 were evaluated. Patients diagnosed with a hyperosmolar 
hyperglycaemic state (HHS) were not included. Seventy patients 
were willing to participate in the study, and signed individual consent 
forms. In the case of participants aged 14 ­ 17 years, an assent form 
was signed. One patient was readmitted twice during the study 
period. All these patients were admitted to the MACU. Three patients 
relapsed after initial resolution and transfer to the general medical 
ward. They were then transferred back to the MACU, and time to 
resolution of the relapsed episode of DKA was recorded. 
Demographic data (age and gender) of participants were obtained. 
Patients were interviewed about past management of their diabetes: 
facility accessed for care, historical DKA rate and recent treatment 
regimens, where known. Initial biochemical parameters were recorded 
on first medical contact, often in the emergency department, prior to 
the initiation of DKA management. The initial blood glucose level was 
ascertained from the first blood gas determination before initiation 
of DKA treatment. Where the latter method was not calibrated, the 
finger­prick glucose value was recorded. The On Call Plus glucometer 
(ACON, USA) was used in the MACU, which records blood glucose 
readings up to 33.3 mmol/L – thereafter recording as ‘HI’ (high). 
For statistical purposes, these readings were excluded from the data 
set, as we could not ascertain the correct value above 33.3 mmol/L. 
Where possible, we tried to identify the precipitant as sepsis, non­
compliance or other. Patients were asked where they would prefer to 
attend follow­up examination after treatment, which was recorded. 
Patients were classified as type 1 or type 2 DM based on clinical 
judgement of the investigator regarding several factors (previously 
known, age of onset, body mass index (BMI), prior antibody testing, 
acanthosis nigricans or polycystic ovary syndrome and family history 
of first­degree relatives with DM). HbA1c was included if measured 
during the current admission or if available from LABTRAK (NHLS, 
SA) within the preceding 3 months. LABTRAK is the only laboratory 
information system that is used by medical staff to access patients’ 
results from any government hospital or clinic in SA. 
Time to resolution of DKA was measured in hours as time from 
start of DKA treatment to cessation of insulin therapy, as guided by 
the abovementioned SEMDSA criteria. Any complication or death 
was recorded. 
Ethical approval
The study was approved by the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. M170551). 
Results
We audited 69 of 71 patients admitted during the study period. One 
patient aged 13 years was excluded from the study. The primary 
outcome was achieved in all, i.e. DKA was resolved in each patient, 
using only insulin in the form of hourly IV boluses. There were no 
deaths; therefore, early survival in our cohort was 100%. 
The average age of participants was 36 (range 27 ­ 52) years, with 
60.56% male patients. Initial biochemistry is detailed in Table 2. 
There were 46.48% and 53.52% type 1 and type 2 DM patients, 
respectively. Some patients (38.03%) reported previous admissions 
owing to DKA, with an average of 2 episodes per participant within 
this group. The mean HbA1c measurement was 13.87% (standard 
deviation (SD) 2.5), with values available from 62 participants. 
Severity was as follows: mild (19.72%), moderate (50.7%) and severe 
(29.58%). The average time to resolution was 21 (13.5 ­ 29) hours. 
Excluding severe DKA, mild and moderate DKA had an average 
time to resolution of 20 hours. There were 32.39% patients who 
were newly diagnosed with DM, with this episode of DKA as their 
index presentation. Of the patients known to have DM, previous 
follow­up visits for medication and monitoring are depicted in Fig. 1. 
Some patients (47.85%) were previously followed up at CHBAH, 
with the second largest proportion from primary healthcare clinics 
(34.78%). Of the 3 patients with DKA who relapsed, complete 
resolution was achieved in 8, 12 and 24 hours of further DKA 
treatment, respectively. No specific factors were identified to explain 
why these patients relapsed. One patient was readmitted twice after 
initial presentation with moderate and severe DKA, non­compliance 
Table 1. Diabetic ketoacidosis admissions, August 2016 - 
January 2017
Month n
August 2016 24
September 2016 36
October 2016 26
November 2016 27
December 2016 19
January 2017 28
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being the precipitant to each episode. This patient was extensively 
counselled and the social services department was consulted to assist 
him. At his last visit, the HbA1c had declined (from 16.6% to 9.1%, 
measured after 3 months). 
Forty­nine patients could account for their previous treatment 
regimens, most receiving insulin twice daily (Fig. 2). The majority 
of patients (74.65%) were issued follow­up dates at CHBAH after 
discharge. Precipitants were identified as sepsis (15.71%), non­
compliance (47.14%) and other/unknown (37.14%). Complications 
occurred in 9 patients (12.68%). Most of these were related to initial 
septic precipitants, i.e. surgical procedures aimed at source control, 
including incision and drainage of a thumb abscess, axillary abscess 
and below­the­knee amputation of a septic diabetic foot. Two 
patients had upper gastrointestinal bleeding during their admission. 
One patient who presented with severe DKA and a low Glascow 
coma scale developed aspiration pneumonia that resolved with IV 
administration of antibiotics. Two patients, one with a pyogenic 
liver abscess and the other with a pancreatic pseudocyst, needed 
drainage of intra­abdominal collections. Both lesions were drained 
using percutaneous pigtail catheters. All patients recovered and were 
subsequently discharged. 
Time to resolution was divided into ˂24 h and >24 h to determine 
which factors influenced a longer time to recovery. These time 
periods were chosen, as the median time was 21 h; therefore, it was 
evaluated in which patients duration to recovery was >24 h. Logistic 
regression analysis showed an association between severity of DKA 
and time to resolution, with an odds ratio of 4.89 (confidence interval 1.04 
­ 22.84; p=0.044). No other factors significantly influenced duration 
of treatment. No correlation was found between the inflammatory 
markers C­reactive protein and white cell count. Both were above 
the normal range in 64.79% of patients, despite no identifiable sepsis 
in the majority of admissions (90.14%); elevation probably resulted 
from acidosis. Most patients presented with renal impairment, 
urea and creatinine being deranged in 60.56% and 64.79% of cases, 
respectively. No patients required dialysis.
Discussion
Managing DKA by bolus IV insulin as opposed to CII has been 
incorporated into protocols in SA and abroad, even though there 
is no strong evidence.[8,14] This audit shows that IV boluses of low­
dose insulin can be successfully used to treat DKA, regardless of 
severity. Our primary objective was to prove that this method is 
effective; therefore, there is a need to define the meaning of efficacy 
in this context. There were no deaths in our cohort, as opposed to 
other DKA studies done in Africa. SA studies quote a mortality 
rate of 7.5% and 6.8% over a 2­ and 12­month period, respectively, 
for hyperglycaemic emergencies (DKA and HHS).[15,16] Mortality 
statistics for the rest of the African subcontinent are estimated at 
>25%.[17] Managing severe DKA with reduced mortality out of the 
ICU would be a great advantage and cost benefit to any hospital. 
Time to resolution could be evaluated as a function of efficacy. Our 
average time to resolution was 21 h, slightly longer than that in most 
other studies in which different insulin treatment regimens were 
used. Studies with similar biochemical inclusion criteria showed a 
mean time to resolution of 17 h, 18.7 h and 19.85 h, respectively. CII 
was employed for the first 2 studies and SC bolus injections for the 
last.[18­20] A Cochrane review evaluating SC bolus IV insulin reported 
a time to resolution of 11 h in 5 RCTs.[21] This study, however, only 
evaluated participants with mild to moderate DKA. Analysis of our 
data showed that severe DKA was correlated with a longer time 
to resolution, which could be an explanation for the shorter time 
to resolution observed in the previous study.[21] There are notable 
differences between our sample and the abovementioned studies: 
Table 2. Initial biochemistry pretreatment
Result Mean/median (IQR or SD) Reference range
Glucose, mmol/L 30 (24.0 ­ 38.5) 3.6 ­ 11.1 
pH 7.14 (6.98 ­ 7.25) 7.35 ­ 7.45
Bicarbonate, mmol/L 8.6 (6.9 ­ 13.0) 21 ­ 28 
Base deficit, mmol/L −20 (13.3 ­ 24.5) −4 ­ 4 
Potassium, mmol/L 5.1 (1.41) 3.5 ­ 5.1 
Urea, mmol/L 9 (5.2 ­ 14.9) 2.1 ­ 7.1 
Creatinine, µmol/L 118 (91 ­ 182) 64 ­ 104 
White cell count, × 109/L 12.37 (8.69 ­ 21.06) 3.92 ­ 10.40 
C­reactive protein, mg/mL 13 (4 ­ 31) 0 ­ 10 
IQR = interquartile range; SD = standard deviation.
Primary
Regional
Tertiary (not CHBAH)
CHBAH MOPD
CHBAH DM clinic
OHA
Basal bolus
Once-daily insulin
Twice-daily insulin
Combo OHA and insulin
35%
28%
20%
49%
8%
21%
20%
2%
4%
13%
Fig. 1. Follow-up care. (CHBAH = Chris Hani Baragwanath Academic Hospital; 
MOPD = medical outpatient department; DM = diabetes mellitus.)
Primary
Regional
Tertiary (not CHBAH)
CHBAH MOPD
CHBAH DM clinic
OHA
Basal bolus
Once-daily insulin
Twice-daily insulin
Combo OHA and insulin
35%
28%
20%
49%
8%
21%
20%
2%
4%
13%
Fig. 2. Previous medication regimen. (OHA = oral hypoglycaemic agents.)
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they were performed in developed­world settings, demographics 
were different, children were included as participants, insulin 
analogues were sometimes used as opposed to human insulin and 
patients were mostly managed in an ICU setting. It is, however, not 
clear whether time to resolution has any impact on improved clinical 
outcomes; therefore, this cannot necessarily be used to prove efficacy 
until further studies are performed.[5]
The number of DKA admissions of 26.67 per month is historically 
similar to that in previous SA studies, i.e. Groote Schuur Hospital in 
1991 and CHBAH in 1986.[22,23] Zouvanis et al.[16] evaluated patients 
with severe DKA (pH <7.25, which equates to moderate and severe 
DKA in our study) at an academic hospital in Johannesburg. The 
majority of patients were aged >40 years, as opposed to our average 
of 36 years. The percentage of newly diagnosed patients with DM 
(31%) was similar to that in our data, as was the proportion of type 1 
to type 2 DM. An identifiable precipitant was present in two­thirds of 
participants, which was in keeping with our data; however, infection 
was more common than non­compliance. There were no deaths in 
the DKA group. 
The majority of patients in our sample presented with moderate 
DKA and some degree of renal impairment, while a large majority 
showed an initial potassium reading at the upper limit of normal or 
high (National Health Laboratory Service (NHLS) 3.5 ­ 5.1 mmol/L). 
This increased potassium reading does not represent total body 
potassium, but instead diminished renal tubular secretion in addition 
to hydrogen­potassium shifts across the cellular membrane.[24] 
Inflammatory markers were raised in the majority of patients, not 
always correlating with the presence of sepsis, which was possibly 
caused by acidosis.[25]
Low­dose insulin given as a hourly IV bolus has been found to be 
just as effective as a pharmacological high­dose in a study with 9 parti ­
ci pants.[26] The main clinical benefit observed was the reduced rates 
of hypokalaemia and hypoglycaemia. Fisher et al.[11] randomised 
15 patients to an hourly IV, SC or IM bolus of 7 IU insulin, observing 
no difference after 8 hours in rates of decline of glucose or serum 
ketones. Similarly, Clumeck et al.[8] administered hourly low­dose 
insulin at 5 IU IV in 19 patients with DKA. Once glucose had reached 
13.9 mmol/L, insulin was changed to SC 6­hourly doses, regardless of 
whether ketonaemia had resolved. Very small numbers were used in 
these landmark studies.
IM insulin has an unpredictable absorption and may accumulate 
in tissues, resulting in delayed hypoglycaemia.[9] It may also be 
unacceptable to the patient, as injections are painful and need to be 
administered several times. Umpierrez et al.[27,28] proved that CII or 
SC insulin analogues are as effective as regular human insulin, which 
must be balanced against their increased cost and lesser availability. 
SC insulin is a reasonable alternative to treat patients with mild to 
moderate DKA. Human insulin, used effectively in this audit, has the 
advantage over insulin analogues in a lower­income country such as 
SA, as it is readily available and has a cost advantage.
Study limitations 
There were several limitations to this study. A large portion of 
data was self­reported by patients, which could lead to recall 
bias. Determination of the type of diabetes did not include type 3 
(pancreatic) DM, as in many cases this was not clearly evident from 
patient history, past clinical diagnoses or notes. CHBAH is a very 
busy hospital and complete adherence to DKA protocol by doctors 
and nurses could not be ensured (an audit in this regard might be 
necessary). Blood gas determinations were sometimes not performed 
at precise 2 ­ 4­hourly intervals as recommended, which could affect 
time to resolution. Excluded blood glucose values (7 of 71) resulted 
in a minimally underestimated mean initial blood glucose value. 
DKA was successfully treated in all patients; therefore, Kaplan­Meier 
survival analysis could not be performed, as stated in the study 
protocol.
Conclusions 
This audit is the first of its kind in SA that shows that bolus IV 
insulin management of DKA is a safe and feasible way to manage 
the condition. This method can be used in patients with severe DKA 
who are not in an ICU. It is effective, as the condition of all patients 
with DKA resolved and there were no deaths in our cohort. No 
complications related to bolus insulin administration were observed. 
There was a longer time to resolution, but this does not necessarily 
correlate with increased complications or efficacy of the treatment 
regimen. 
This study could serve as a platform to influence other SA health 
centres to employ this route of insulin administration. Further audits 
could strengthen evidence for its use. Large RCTs are needed to 
compare all routes of administration of insulin and provide clear data 
on the preferred method.
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